Zhaoke Ophthalmology-B (06622): Australia's Therapeutic Goods Administration Accepts Registration Application for Atropine Sulfate Eye Drops

Stock News

Jan 13

Zhaoke Ophthalmology-B (06622) announced that on January 5, 2026, Australia's Therapeutic Goods Administration (TGA) has accepted for review the company's registration application for its Atropine Sulfate Eye Drops (0.01% dosage, product code: NVK002), intended for the treatment of myopia progression in children.

The TGA has formally notified the company that its application has passed the preliminary review and will proceed to a full evaluation.

This application is based on the supportive results obtained from the Phase III clinical trials conducted by the company.

Atropine Sulfate Eye Drops (NVK002) is an investigational novel topical ophthalmic solution for controlling the progression of myopia in children and adolescents.

Atropine Sulfate Eye Drops (NVK002) is a patented formulation that successfully addresses the instability issues of low-concentration atropine, a technology protected by intellectual property rights globally.

The Atropine Sulfate Eye Drops (NVK002) are preservative-free and are expected to have a shelf life of over 24 months.

According to information provided by China Insights Consultancy, NVK002 is currently one of the most advanced atropine candidates globally for treating myopia progression, targeting the broadest patient group covering children and adolescents aged 3 to 17.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1124745629"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1124745629\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1124745629?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 18:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124745629","market":"sh","top_or_hot":-1,"title":"Zhaoke Ophthalmology-B (06622): Australia's Therapeutic Goods Administration Accepts Registration Application for Atropine Sulfate Eye Drops","media":"Stock News","content":"<p>Zhaoke Ophthalmology-B (06622) announced that on January 5, 2026, Australia's Therapeutic Goods Administration (TGA) has accepted for review the company's registration application for its Atropine Sulfate Eye Drops (0.01% dosage, product code: NVK002), intended for the treatment of myopia progression in children.</p>\n<p>The TGA has formally notified the company that its application has passed the preliminary review and will proceed to a full evaluation.</p>\n<p>This application is based on the supportive results obtained from the Phase III clinical trials conducted by the company.</p>\n<p>Atropine Sulfate Eye Drops (NVK002) is an investigational novel topical ophthalmic solution for controlling the progression of myopia in children and adolescents.</p>\n<p>Atropine Sulfate Eye Drops (NVK002) is a patented formulation that successfully addresses the instability issues of low-concentration atropine, a technology protected by intellectual property rights globally.</p>\n<p>The Atropine Sulfate Eye Drops (NVK002) are preservative-free and are expected to have a shelf life of over 24 months.</p>\n<p>According to information provided by China Insights Consultancy, NVK002 is currently one of the most advanced atropine candidates globally for treating myopia progression, targeting the broadest patient group covering children and adolescents aged 3 to 17.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhaoke Ophthalmology-B (06622): Australia's Therapeutic Goods Administration Accepts Registration Application for Atropine Sulfate Eye Drops</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhaoke Ophthalmology-B (06622): Australia's Therapeutic Goods Administration Accepts Registration Application for Atropine Sulfate Eye Drops\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-13 18:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zhaoke Ophthalmology-B (06622) announced that on January 5, 2026, Australia's Therapeutic Goods Administration (TGA) has accepted for review the company's registration application for its Atropine Sulfate Eye Drops (0.01% dosage, product code: NVK002), intended for the treatment of myopia progression in children.</p>\n<p>The TGA has formally notified the company that its application has passed the preliminary review and will proceed to a full evaluation.</p>\n<p>This application is based on the supportive results obtained from the Phase III clinical trials conducted by the company.</p>\n<p>Atropine Sulfate Eye Drops (NVK002) is an investigational novel topical ophthalmic solution for controlling the progression of myopia in children and adolescents.</p>\n<p>Atropine Sulfate Eye Drops (NVK002) is a patented formulation that successfully addresses the instability issues of low-concentration atropine, a technology protected by intellectual property rights globally.</p>\n<p>The Atropine Sulfate Eye Drops (NVK002) are preservative-free and are expected to have a shelf life of over 24 months.</p>\n<p>According to information provided by China Insights Consultancy, NVK002 is currently one of the most advanced atropine candidates globally for treating myopia progression, targeting the broadest patient group covering children and adolescents aged 3 to 17.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1124745629","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124745629","pubTimestamp":1768299337,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhaoke Ophthalmology-B (06622) announced that on January 5, 2026, Australia's Therapeutic Goods Administration (TGA) has accepted for review the company's registration application for its Atropine...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1587":"次新股","BK1574":"生物医药B类股","BK1583":"高瓴概念","06622":"兆科眼科-B"},"translate_title":"兆科眼科-B(06622)：澳洲治疗用品管理局受理硫酸阿托品滴眼液注册申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06622":1},"content_text":"Zhaoke Ophthalmology-B (06622) announced that on January 5, 2026, Australia's Therapeutic Goods Administration (TGA) has accepted for review the company's registration application for its Atropine Sulfate Eye Drops (0.01% dosage, product code: NVK002), intended for the treatment of myopia progression in children.\nThe TGA has formally notified the company that its application has passed the preliminary review and will proceed to a full evaluation.\nThis application is based on the supportive results obtained from the Phase III clinical trials conducted by the company.\nAtropine Sulfate Eye Drops (NVK002) is an investigational novel topical ophthalmic solution for controlling the progression of myopia in children and adolescents.\nAtropine Sulfate Eye Drops (NVK002) is a patented formulation that successfully addresses the instability issues of low-concentration atropine, a technology protected by intellectual property rights globally.\nThe Atropine Sulfate Eye Drops (NVK002) are preservative-free and are expected to have a shelf life of over 24 months.\nAccording to information provided by China Insights Consultancy, NVK002 is currently one of the most advanced atropine candidates globally for treating myopia progression, targeting the broadest patient group covering children and adolescents aged 3 to 17.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}